Fangming Xu

Fangming Xu

Auto-generated profile, based on publicly available information

Fangming Xu

Department of Pharmacy, Shaoxing People’s Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YDYongqiang Dong
Yongqiang Dong
XWXudong Wu
Xudong Wu
XCXuerong Chen
Xuerong Chen
PZPing Zhou
Ping Zhou
FXFangming Xu
Fangming Xu
WLWenqing Liang
Wenqing Liang
Currently, stem cell nanotechnology is one of the novel and exciting fields. Certain experimental studies conducted on the interaction of stem cells with nanostructures or nanomaterials have made significant progress. The significance of nanostructures, nanotechnology, and nanomaterials in the development of stem cell-based therapies for degenerative diseases and injuries has been well established. Specifically, the structure and properties of nanomaterials affecting the propagation and differentiation of stem cells have become a new interdisciplinary frontier in material science and regeneration medicines. In the current review, we highlight the recent major progress in this field, explore the application prospects, and discuss the issues, approaches, and challenges, to improve the applications of nanotechnology in the research and development of stem cells.

8 August 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
LZLin Zhang
Lin Zhang
CZChao Zhou
Chao Zhou
SZSongou Zhang
Songou Zhang
XCXiaozhen Chen
Xiaozhen Chen
JLJian Liu
Jian Liu
WLWenqing Liang
Wenqing Liang
New evidence suggests that the clinical success of chemotherapy is not merely due to tumor cell toxicity but also arises from the restoration of immunosurveillance, which has been immensely neglected in previous preclinical and clinical researches. There is an urgent need for novel insights into molecular mechanisms and regimens that uplift the efficacy of immunotherapy since only a minority of cancer patients are responsive to immune checkpoint inhibitors (ICIs). Recent findings on combination therapy of chemotherapy and ICIs have shown promising results. This strategy increases tumor recognition and elimination by the host immune system while reducing immunosuppression by the tumor microenvironment. Currently, several preclinical studies are investigating molecular mechanisms that give rise to the immunomodulation by chemotherapeutic agents and exploit them in combination therapy with ICIs in order to achieve a synergistic clinical activity. In this review, we summarize studies that exhibit the capacity of conventional chemotherapeutics to elicit anti-tumor immune responses, thereby facilitating anti-tumor activities of the ICIs. In conclusion, combining chemotherapeutics with ICIs appears to be a promising approach for improving cancer treatment outcomes.

1 October 2021 in Molecular Immunology
Verified
Journal Article
Closed access
JPJianfeng Ping
Jianfeng Ping
CZChao Zhou
Chao Zhou
YDYongqiang Dong
Yongqiang Dong
XWXudong Wu
Xudong Wu
XHXiaogang Huang
Xiaogang Huang
WLWenqing Liang
Wenqing Liang

22 January 2021 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
WLWenqing Liang
Wenqing Liang
XWXudong Wu
Xudong Wu
YDYongqiang Dong
Yongqiang Dong
RSRuyi Shao
Ruyi Shao
XCXuerong Chen
Xuerong Chen
FXFangming Xu
Fangming Xu
This review presents the recent advances and the current state-of-the-art of bioactive glass-based composite biomaterials intended for bone regeneration. Composite materials comprise two (or more) constituents at the nanometre scale, in which typically, one constituent is organic and functions as the matrix phase and the other constituent is inorganic and behaves as the reinforcing phase. Such materials, thereby, more closely resemble natural bio-nanocomposites such as bone. Various glass compositions in combination with a wide range of natural and synthetic polymers have been evaluated in vivo under experimental conditions ranging from unloaded critical-sized defects to mechanically-loaded, weight-bearing sites with highly favourable outcomes. Additional possibilities include controlled release of anti-osteoporotic drugs, ions, antibiotics, pro-angiogenic substances and pro-osteogenic substances. Histological and morphological evaluations suggest the formation of new, highly vascularised bone that displays signs of remodelling over time. With the possibility to tailor the mechanical and chemical properties through careful selection of individual components, as well as the overall geometry (from mesoporous particles and micro-/nanospheres to 3D scaffolds and coatings) through innovative manufacturing processes, such biomaterials present exciting new avenues for bone repair and regeneration.

27 December 2021 in Journal of Tissue Engineering and Regenerative Medicine
Verified
Journal Article
Closed access
PDF file
JPJianfeng Ping
Jianfeng Ping
LLLaifeng Li
Laifeng Li
YDYongqiang Dong
Yongqiang Dong
XWXudong Wu
Xudong Wu
XHXiaogang Huang
Xiaogang Huang
WLWenqing Liang
Wenqing Liang

19 October 2021 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
WLWenqing Liang
Wenqing Liang
XWXudong Wu
Xudong Wu
YDYongqiang Dong
Yongqiang Dong
XCXuerong Chen
Xuerong Chen
PZPing Zhou
Ping Zhou
FXFangming Xu
Fangming Xu